News & Updates

In the real-world treatment of older adults with inflammatory bowel disease (IBD), the cardiovascular safety of ustekinumab is similar to that of vedolizumab, with no significant difference in the risk of major adverse cardiovascular events (MACE). However, ustekinumab is associated with a reduced risk of all-cause mortality.

Pregnant women with colorectal cancer (CRC) face a considerably increased likelihood of severe maternal morbidity, including disseminated intravascular coagulation, acute respiratory distress syndrome, and hysterectomy, among others, according to a study.